SCHEMBL2187339

SCHEMBL2187339

CCNC(=O)c1nc(F)sc1-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.52
NPC1 O15118 3/20 0.52
PIN1 Q13526 1/20 0.51
ALDH1A1 P00352 6/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HSD17B10 Q99714 2/20 0.45
KDM4E B2RXH2 1/20 0.45
HSP90AB1 P08238 1/20 0.44
GAA P10253 3/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
HDAC4 P56524 1/20 0.41
HDAC3 O15379 1/20 0.41
ABL1 P00519 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
RAB9A P51151 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP1A2 P05177 3/20 0.39
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2186972 0.84 HPGD (0.51) HPGDNPC1PIN1ALDH1A1SMN1; SMN2
SCHEMBL27866747 0.75 KDM4E (0.48) HPGDNPC1ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL2187354 0.73 MAPK14 (0.48) HPGDNPC1ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL9586946 0.70 HDAC3 (0.47) HPGDNPC1ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL19064388 0.70 IP6K1 (0.53) HPGDNPC1PIN1SMN1; SMN2HSP90AB1
SCHEMBL2186986 0.70 MAPK14 (0.46) HPGDNPC1ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL9586464 0.69 HDAC3 (0.44) HPGDNPC1ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL9587054 0.69 ALDH1A1 (0.59) HPGDNPC1ALDH1A1SMN1; SMN2HSD17B10
SCHEMBL4795690 0.69 HCRTR1 (0.66) SMN1; SMN2HDAC1HDAC6HDAC3L3MBTL1
SCHEMBL10242421 0.69 HPGD (0.63) HPGDNPC1PIN1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 HPGD 3481/4885NPC1 1296/4885PIN1 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.